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In a prospective study we determined the frequency and causes of delay in the diagnosis of breast cancer after suspicious screening
mammography. We included all women aged 50–75 years who underwent biennial screening mammography in the southern breast
cancer screening region of the Netherlands between 1 January 1996 and 1 January 2002. Clinical data, breast imaging reports, biopsy
results and breast surgery reports were collected of all women with a positive screening result with a minimum of 2-year follow-up.
Of 153969 mammographic screening examinations, 1615 (1.05%) were positive screens. Breast cancer was diagnosed in 770
(47.9%) of 1607 women for whom follow-up information was available, yielding a cancer detection rate of 5.0 per 1000 women
screened. Breast cancer was diagnosed within 3 months following a positive screen in 722 cases (93.8%). The diagnostic delay was 4–
6, 7–12 and 13–24 months, respectively, in 11 (1.4%), 24 (3.1%) and nine (1.2%) patients. In four other patients (0.5%), breast
cancer was diagnosed after a repeat positive screen, resulting in a diagnostic delay of 25–27 months. Reasons for a diagnostic delay
43 months were erroneous mammographic interpretation of suspicious lesions as benign or probably benign lesions (33 cases),
benign biopsies from a malignant lesion (10), and omission to biopsy or remove a lesion that was suspicious at breast imaging (4) or
core biopsy (1). We conclude that there is room for improvement in the workup of patients with a positive screening
mammography, as seen from data in this screening region. To improve the workup, we suggest that other breast cancer screening
programmes also identify delay in breast cancer diagnosis after a positive screen.
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Breast cancer is the most frequent malignancy among women in
developed countries (Parkin et al, 1997; Parkin, 2001). Breast
screening aims to detect breast cancers as small as possible and
before lymph node dissemination. Randomised trials of mammo-
graphic screening have provided strong evidence that early
diagnosis and treatment of breast cancer reduce breast cancer
mortality (Nystrom et al, 2002).
In the Netherlands, a nation-wide breast cancer screening
programme was gradually implemented from 1989 till 1997
(Fracheboud et al, 2001). The programme initially offered biennial
screening mammography to women aged 50–69 years; in 1998 the
upper age limit was extended to 75 years. The overall attendance
rate is 80%; today, about 800000 screening examinations per year
are performed at 63 fixed or mobile screening units.
Screening does not end at the early recognition of mammo-
graphic abnormalities that are suspect for breast cancer: a prompt
diagnostic follow-up is important as well. Delay in the diagnosis of
breast cancer, however, frequently occurs. In the United States,
physician delay is the most common cause of malpractice (Kern,
1994; Physician Insurers Association of America, 2003), often
involving the inappropriate reassurance that a palpable mass is
benign without having performed biopsy (Goodson and Moore,
2002). In mammography screening programmes, mammographic
abnormalities usually are nonpalpable. To our knowledge, no
prospective data of the frequency and the reasons of diagnostic
delay of non-palpable breast cancers are available.
The aim of this observational follow-up study was to determine
the frequency and causes of delay in the diagnosis of breast cancer
after suspicious mammographic findings at screening.
MATERIALS AND METHODS
Study population and screening procedure
We included all women who underwent screening mammography
at one of two specialised screening units (one fixed and one
mobile) in the southern breast cancer screening region of the
Netherlands (BOBZ, Bevolkings Onderzoek Borstkanker Zuid)
between 1 January 1996 and 1 January 2002. Details of the nation-
wide breast cancer screening programme have been described
previously (Fracheboud et al, 1998; Duijm et al, 2004). In brief,
women aged 50–75 years are invited by letter every 2 years to
attend breast screening. In initial screens, that is, the first time
women are screened within the screening programme, two-view
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l(medio-lateral-oblique and cranio-caudal) mammography of
each breast is performed. In subsequent screens one-view
mammography is standard, though two-view mammography is
obtained in 20–30% of subsequent screens; the indications include
complicated judgement due to breast surgery or dense fibrogland-
ular tissue; any changes in mammographic findings; and a longer-
than-2-year interval since the previous screen. All examinations
are read independently by two certified screening radiologists.
Women with normal or benign mammographic findings or with
nonspecific minimal signs are not referred for further diagnostic
workup (Maes et al, 1997). In case of suspicious or malignant
lesions, the general practitioner (GP) refers the woman to a
surgical oncologist in a regional hospital. After physical examina-
tion by the surgeon, a two-view mammogram of each breast is
obtained; local compression or magnification mammograms are
performed if necessary. Depending on the diagnostic workup
protocols and the facilities available, further evaluation may also
include breast ultrasonography, magnetic resonance mammogra-
phy, fine needle aspiration biopsy (FNAB, cytology) or histologic
core biopsy or excision biopsy (Kwaliteitsinstituut voor de
Gezondheidszorg CBO, 2000). The 1999 Dutch national guidelines
for the early detection and diagnosis of breast cancer recommend
that the diagnostic process should be completed within 4 weeks in
at least 90% of patients to minimise the period of uncertainty. In
our study, we defined a longer-than-3-month interval between the
positive breast screening and the confirmation of breast cancer as
diagnostic delay.
Screening follow-up
We collected data on diagnostic procedures, breast cancer
diagnosis, histopathology and TNM-classification for all women
with a positive screening. The follow-up of women with a positive
screening included the period through the next screening round
(with a screening interval of about 2 years). In total, 13 women
died during follow-up; linkage with the pathology laboratories
showed that none of these women had suffered from breast cancer.
Following standard procedures, the GP informed the BOBZ
screening organisation to which hospital the woman had been
referred. At 3–6 months after the referral, the BOBZ collected the
copies of radiology reports and of surgical records for each
referred woman. In addition, breast pathology reports were
obtained from the regional pathology laboratories, and radio-
therapy reports from the regional radiotherapy institute. To trace
breast cancers diagnosed more than 6 months after referral,
information in addition to the standard follow-up procedure was
sought: (a) inquiry about pathology specimens of women with a
repeat positive screen for the same lesion that had been considered
benign at workup 2 years before; (b) linkage with the regional
pathology laboratories of women who had not re-attended
screening 2 years after a false positive screening (mammographic
screening was defined as false-positive if further diagnostics after
referral proved to be negative); and (c) linkage to the regional
Register of Deaths (Gemeentelijke Basisadministratie Persoonsge-
gevens) 2 years after a false-positive screen.
For cases with bilateral disease, the cancer with the highest stage
was retained and multiple foci of cancer in one breast were
counted as one cancer.
To determine whether a delay in breast cancer diagnosis could
be attributed to the radiological assessment, two dedicated breast
radiologists (LD, FJ) independently and retrospectively reviewed
the diagnostic breast images of all women with diagnostic delay.
Each reviewer classified the lesions using the Breast Imaging
Reporting and Data System BI-RADS (American College of
Radiology, 1998). For BI-RADS three lesions (nonpalpable
probably benign lesions), the criteria published by Sickles (1991)
and by Varas et al (2002) were used.
Workup facilities
One of the authors (LD) inquired at the hospitals involved in the
diagnostic workup whether an outpatient breast clinic was present;
whether sophisticated diagnostic modalities such as magnetic
resonance mammography and stereotactic core biopsy were
available; whether the follow-up results of women with a positive
screen were regularly discussed by a multidisciplinary team of
clinicians, radiologists and pathologists; and whether the hospital
radiologists also participated in the nation-wide breast cancer
screening programme.
All women included in our study had given written informed
consent to use their data for scientific purposes before participa-
tion in the screening programme. Institutional review board
approval was not required for this type of study.
RESULTS
Referral and diagnostic follow-up examinations
A total of 153969 mammographic screening examinations were
performed: 41683 were initial screens and 112286 were subsequent
screens. The mean age of the screened women was 58 years (range
50–75 years). In total, 1615 women were referred for further
diagnostic examination (Table 1). The mammographic features at
screening were density (75.9%), microcalcifications (14.6%),
density with microcalcifications (6.4%), asymmetry of breast
parenchyma (1.3%) or architectural distortion (1.8%). Diagnostic
workup was performed in 1607 women (99.5%); five other women
refused further assessment; workup was refrained from in one
woman with metastasised lung cancer; and the GPs of two women
reported that the mammographic lesion had remained unchanged
for several years and that workup was not indicated. The period
between the date of the positive mammogram and the first hospital
visit was less than 3 weeks in all but two women: one woman could
be contacted only 6 weeks after the screening examination, the
other woman agreed with further workup 2 months following the
positive screen. Of the women referred at first screens, 68.2%
underwent biopsy, and 65.0% of the women referred at subsequent
screens; the biopsy rates (percutaneous or open surgical) were 9.7
and 5.9 per 1000 screened women, respectively.
Breast cancer diagnosis
In total, 770 histologically proven breast cancers were diagnosed,
yielding an overall cancer detection rate of 5.0 per 1000 women
screened and a true-positive referral rate of 47.9% (Table 1). Breast
cancer was diagnosed within 3 months following a positive screen
in 722 women (93.8%). The diagnostic delay exceeded 3 months in
48 women (6.2%); 19 cases involved initial screens and 29 cases
involved subsequent screens (screening interval o30 months: 26
women; screening interval X30 months: three women). The delay
was 4–6 months in 11 women (1.4%), 7–12 months in 24 women
(3.1%) and 13–24 months in nine women (1.2%); all these women
had remained under physical and radiological surveillance after
the initial assessment. In four other women (0.5%), breast cancer
was diagnosed after referral in the next screening round for the
same lesion that had been considered benign at workup 2 years
before; in these cases, the diagnostic delay was 25–27 months. The
tumour size distribution and axillary lymph node status are
presented in Table 2. In 11 of the 48 women with a diagnostic delay
ductal cancer in situ (DCIS) was diagnosed (22.9%); six women
(12.5%) had T2þ-tumours (420mm), and nine women (18.8%)
had axillary lymph node metastases. For cancers diagnosed within
3 months following a positive screen, the percentages of DCIS,
T2þ-tumours and lymph node metastases were 15.5, 20.5 and
25.3%, respectively.
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The reasons that contributed to a diagnostic delay are listed in
Table 3. In total, 33 cancers that had been classified as BI-RADS 1–
3 mammograms at workup were categorised as BI-RADS 4 or 5
lesions on review: the mammographic features were density in
24 cases (72.7%), clustered calcifications in seven cases (21.2%),
density with microcalcifications in one case (3.0%) and architec-
tural distortion in one case (3.0%). In 10 patients the biopsy result
proved to have been false-negative; the surgeon had not repeated
biopsy despite the radiologist’s explicit advice in six women,
whereas clinical oncologists had followed four other women
clinically despite suspicious mammograms needing further eva-
luation by biopsy. In one other case the surgeon did not remove a
lesion after a probably malignant core biopsy result. During the
6-year inclusion period, the proportion of screen-detected cancers
with diagnostic delay varied: this proportion was 9.5% (15 out of
158) in 1996; 4.7% (five out of 107) in 1997; 6.0% (seven out of 116)
in 1998; 4.2% (five out of 120) in 1999; 6.7% (10 out of 149) in
2000; and 5.0% (six out of 120) in 2001.
Screening workup facilities
At the beginning of our study in 1996, none of the eight hospitals
involved in the workup of a positive screening mammogram had
an outpatient breast clinic; in early 2004 this facility was available
in all but one hospital. In 1998, magnetic resonance mammo-
graphy had been introduced in one hospital; this modality is
currently available at five sites. Stereotactic core biopsy of
Table 1 Referral and diagnostic follow-up for initial and subsequent screens between 1 January 1996 and 1 January 2002
Subsequent screens
Initial screens Interval o30 mo Interval X30mo All subsequent screens Total
N¼41683 N¼106035 N¼6251 N¼112286 N¼153969
Referrals (N) 592 914 109 1023 1615
Referral rate (per 1000 women screened) 14.2 8.6 17.4 9.1 10.5
N % N % N % N % N %
Diagnostic follow-up available
a 587 99.2 911 99.7 109 100.0 1020 99.7 1607 99.5
Diagnostic procedures
b
Breast imaging 183 31.2 330 36.2 25 22.9 355 34.8 538 33.5
FNAB (cytology) 18 3.1 44 4.8 8 7.3 52 5.1 70 4.4
Surgical or core biopsy 386 65.8 537 58.9 76 69.7 613 60.1 999 62.2
Outcome
Breast cancer
c 273 46.5 431 47.3 66 60.6 497 48.7 770 47.9
No breast cancer 314 53.5 480 52.7 43 39.4 523 51.3 837 52.1
Biopsy rate (per 1000 women screened) 9.7 5.5 13.4 5.9 6.9
Detection rate (per 1000 women screened) 6.5 4.1 10.6 4.4 5.0
Positive predictive value of referral (%) 46.5 47.3 60.6 48.7 47.9
Positive predictive value of biopsy (%)
d 67.6 74.2 78.6 74.7 72.0
aDiagnostic follow-up was missing for eight women: five patients refused any kind of workup after a positive screen; workup remained undone in one patient who also had
metastasised lung cancer; the general practitioners of two other women reported that the screen-detected lesion had remained unchanged for several years and that referral
therefore was not indicated.
bThe diagnostic procedures were classified according to the most invasive diagnostic technique. In all instances, the women underwent clinical breast
examination as well. The women who underwent FNAB or histological (surgical or core) biopsy also had had breast imaging.
cOf 770 breast cancers, 48 were diagnosed more
than 3 months after the positive mammographic screening.
dThe eight cases without follow-up were excluded from these analyses.
Table 2 Tumour size distribution and lymph node metastases by diagnostic delay
Diagnostic delay
p3m o( N¼722) 43m o( N¼48) Total (N¼770) National figures (N¼17084)
a
No. % No. % No. % No. %
Type of breast cancer
DCIS 112 15.5 11 22.9 123 16.0 2457 14.6
Invasive 610 84.5 37 77.1 647 84.0 14352 85.4
T1a/b/c 483 79.2 31 83.8 514 79.4 76.1
T2+ 125 20.5 6 16.2 131 20.2 21.9
Unknown 2 0.3 0 0.0 2 0.3 2.0
Lymph-node status of invasive cancers
Positive
b 183 30.0 9 24.3 192 29.7 26.0
Negative 409 67.0 28 75.7 437 67.5 67.9
Unknown 18 3.0 0 0 18 2.8 6.0
aUnpublished data. For 275 breast cancers, it was not known whether they were DCIS or invasive cancers. Source: NETB (2001). Figures for screen-detected breast cancers,
1996–2001.
bIncluding cases with distant metastases.
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hospitals between 1996 and 2002 and is now routine practice at all
sites. Regular discussion of positive screens by a multidisciplinary
team had been established in four hospitals between 2001 and
2003; there is no such multidisciplinary approach at the other four
sites. Screening radiologists are involved in the workup of screened
patients at three hospitals.
DISCUSSION
In our series, the delay in breast cancer diagnosis after a positive
screening mammogram exceeded 3 months in 6.2% of the referred
women, and 6 months in 4.8%. Delay in the diagnosis of breast
cancer is not uncommon. Tartter et al (1999) found that 8% of
patients in a New York Breast Service had a diagnostic delay of
over 3 months from their first consultation for the breast problem
that was eventually proven to result from a malignancy. In three
other series, including both symptomatic and asymptomatic
women, the delay exceeded 3 months in 4–39% (Jenner et al,
2000; Montella et al, 2001; Goodson and Moore, 2002). Barber et al
(2004) recently described that 1.4% of symptomatic patients in a
British breast clinic experienced a delay exceeding 2 months.
The tumour stages of breast cancers with a delayed diagnosis in
our study were more favourable compared with cancers diagnosed
within 3 months of a positive screen. In contrast, a Canadian study
showed that screen-detected breast cancers diagnosed between 20
and 52 weeks after mammographic screening more often had a
larger tumour size or lymph node metastases compared with
breast cancers diagnosed within 4–12 weeks of an abnormal
screen (Olivotto et al, 2002). Our findings may be explained by
diagnostic suspicion bias: the workup may have been more
aggressive for mammographic features highly suggestive of cancer.
There are conflicting reports whether diagnostic delay is associated
with lower survival. Afzelius et al (1994) concluded that physician
delay of more than 60 days was not associated with an unfavourable
outcome. A systematic review, however, showed that a delay of 3–6
months in symptomatic patients was associated with lower survival
(Richards et al, 1999). It is unknown if this adverse effect also applies
to screen-detected (asymptomatic) breast cancers. An accurate and
timely diagnosis, however, will minimise patient anxiety.
In our series, two-thirds of the diagnostic delay resulted from an
incorrect classification of the diagnostic mammography, most
frequently the erroneous classification into the BI-RADS 3 category
of suspicious mammograms. Barber et al (2004) also found that
misinterpretation of mammographic lesions as benign was one of
the most common reasons for diagnostic delay. In an American
study, malignant lesions for which short-term mammographic
follow-up was recommended often did not fulfil the criteria for
probably benign lesions in retrospect (Rosen et al, 2002). Other
studies have consistently found that no more than 1–2% of lesions
characterised as ‘probably benign’ actually turn out to be
cancerous (Vizcaı ´no et al, 2001; Yasmeen et al, 2003).
Other reasons for the diagnostic delay in our series were false
negative biopsy results or disregard of the radiologist’s advise to
biopsy, a radiologically suspicious lesion. Special breast care units
and multidisciplinary teams may improve the assessment of
symptomatic breast disease (Purushotham et al,2 0 0 1 ;H a w a r d
et al, 2003). In our country, breast cancer screening must be
performed by certified facilities and certified screening radiologists;
the workup of a positive screen, however, can take place in any
hospital. Only a quarter of the hospitals in our study had outpatient
breast clinics or held multidisciplinary meetings. Involving screen-
ing radiologists in the workup may be important as Dutch residents
in radiology and general radiologists do not need specific knowledge
of breast cancer screening. The frequency of diagnostic delay
exceeding 3 months did not tend to decline during the study period.
Whether delay in breast cancer diagnosis is correlated with the
workup facilities at the hospitals, which since have improved,
remains to be seen. The national guidelines for the early detection
and diagnosis of breast cancer, published in 1999, may have
influenced the course of the diagnostic process in later years as well.
We conclude that the workup of patients with a positive screening
mammogram needs improvement. Services within hospitals need to
be organised in order to prevent unnecessary diagnostic delay. To
improve the workup after recall, we suggest that other breast cancer
screening programmes also identify women with a delay in breast
cancer diagnosis after a positive screen.
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